What we do Wanbury Limited is a pharmaceutical company engaged in manufacturing APIs and formulations, focusing on research and supplying global regulated markets. |
Founded in 1,988 |
Market share Globally significant market share in Metformin (~11%) and Sertraline (~30%) APIs. |
Problem solved Provides affordable and high-quality medicines addressing chronic and acute health conditions including diabetes and mental health. |
Top clients or who we serve Serves pharmaceutical companies and healthcare providers globally, including regulated markets in US, Europe, Brazil, and India; B2B and B2C. |
Key management - |
Our journey and innovations Founded as Pearl Organics in 1988, underwent mergers and strategic alliances, expanded manufacturing in India and abroad, launched key products like Cdense Gems and Myotol-F. |
Where we operate Operations primarily in India with subsidiaries in Netherlands, UAE, China, and Spain; exports to 50+ countries worldwide. |
Top products or what we offer APIs including Metformin, Sertraline, Tramadol; formulations in anti-cold, pain relief, supplements, and specialty medicines. |
Top brands Cdense Gems, Myotol-F, Folinine, Cal-K2; multiple acute and chronic care formulations brands in India. |
Raw materials needed Key chemicals and intermediates for API synthesis such as solvents, catalysts, and medicinal grade compounds. |
Raw materials supplier Imports raw materials from China and other global suppliers; strategic sourcing via Ningxia Wanbury Fine Chemicals Co Ltd. |
Recurring vs cyclical contribution Revenue is primarily recurring from long-term API contracts and branded formulations sales. |
Our industry position Well-positioned API supplier with multiple USFDA approvals; growing branded formulations business in India. |
Financial highlights FY25 revenue ₹599.51 crore; net profit ₹30.53 crore; EBITDA margin approx. 13%; steady growth over 5 years. |
Geographical revenue split FY25 revenues: 58% from outside India (₹413.86 crore), 42% domestic (₹179.68 crore). |
Order book - |
Whats driving growth API demand growth, product launches, capacity expansions, market penetration in regulated markets, operational efficiencies. |
Our future plans Launch four new API molecules yearly from FY27; expand formulations with specialty therapies; enhance manufacturing capacities. |
Our green promise Investing in zero liquid discharge, solar power projects, and sustainable chemical processes to reduce environmental impact. |
Our people and values Over 1,200 employees; focus on safety, compliance, and inclusive workplace culture. |
Key challenges ahead Managing regulatory compliance in multiple markets, raw material cost volatility, and increasing competition. |
Interesting facts Achieved zero 483 observations in recent USFDA inspection; maintains regulated market approvals since early 2000s. |
Risks and strategy Risks include regulatory changes and supply chain disruptions; mitigation through diversification, backward integration, and R&D investment. |
